Radiation Oncology Journal

  • 제20권3호
  • /
  • Pages.206-214
  • /
  • 2002
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지

하인두암의 방사선치료

Results of Radiotherapy in Hypopharyngeal Cancer

  • 신병철 (고신대학교 의과대학 복음병원 방사선종양학과) ;
  • 염하용 (고신대학교 의과대학 복음병원 방사선종양학과) ;
  • 문창우 (고신대학교 의과대학 복음병원 방사선종양학과) ;
  • 정태식 (고신대학교 의과대학 복음병원 방사선종양학과)
  • Shin Byung Chul (Department of Radiation Oncology, Kosin University Gospel Hospital) ;
  • Yum Ha Yong (Department of Radiation Oncology, Kosin University Gospel Hospital) ;
  • Moon Chang Woo (Department of Radiation Oncology, Kosin University Gospel Hospital) ;
  • Jeong Tae Sik (Department of Radiation Oncology, Kosin University Gospel Hospital)
  • 발행 : 2002.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적 : 하인두암 환자에서 방사선단독치료와 항암화학요법 병용치료시의 반응과 생존율, 그리고 합병증에 영향을 미치는 요소를 알아보고자 하였다. 대상 및 방법 : 1984년 1월부터 1999년 12월까지 고신대학교 복음병원 치료방사선과에서 치료를 받았던 환자 중 근치적 목적으로 방사선치료 단독 또는 항암화학요법과 병용치료를 받았던 56명을 대상으로 후향적 조사를 하였다. 방사선 단독치료(Group I)가 24명$(42.9\%)$, 항암화학방사선치료(Group II)가 32명$(57.1\%)$이었다. 방사선치료는 정규분할 조사법으로 9명$(16.4\%)$, 과분할조사로 분할선량이 $1.15\~1.2\;Gy$인 경우가 26명$(47.2\%)$, 1.35 Gy인 경우가 18명$(32.7\%)$, 가속과분할조사로 2명$(3.6\%)$이 치료받았으며 총 방사선량은 $40.5\~83.5\;Gy$ (평균선량 68.3 Gy)이었다. 항암화학요법은 cisplatin $100\;mg/m^2$을 day 1에, 5-FU $1,000\;mg/m^2$를 day $2\~6$에 방사선치료에 선행해서 사용하였으며 3주 간격으로 시행하였고 환자에 따라 1회에서 3회까지 시행하였다(평균 2.3회). 추적관찰기간은 1개월에서 195개월 이었고 중앙값은 28개월이었다. 결과 : 전체 대상 환자들의 3년 및 5년 생존율은 $40.6\%,\;27.6\%$였고, Group I은 $50.0\%,\;30.0\%$, II는 $36.4\%,\;26.3\%$였다. 국소제어율은 Group I에서 완전관해율이 $70.0\%$, Group II에서는 완전관해율이 $67.7\%$였다. 생존율에 영향을 미치는 예후인자로는 방사선치료에 대한 반응과 림프절 병기로 나타났다. 항암화학요법을 병용한 군에서 합병증 발생율이 높았으나 다분할 조사군에서는 정규분할조사군보다 적게 나타났다. 결론 : 하인두암의 방사선치료 결과는 방사선치료에 대한 반응과 경부 림프절 병기에 따라 좌우되었다. Cisplatin, 5-FU를 방사선치료 전 선행하여 $1\~3$회 사용하는 것은 하인두암의 국소제어율과 생존율에 가치가 없는 것으로 증명되었으며 오히려 합병증을 높이는 것으로 판명되었다. 다분할 방사선치료는 후기 합병증을 저하시키는 것으로 판명되었다.

Purpose : The aim of this study was to assess the effectiveness, survival rate and complications of radiation therapy and chemoradiation treatment in hypopharyngeal cancer. Methods and Materials : From January 1984 to December 1999, 56 patients who had hypopharyngeal carcinoma treated with curative radiation therapy were retrospectively studied. Twenty four patients $(42.9\%)$ were treated with radiation therapy alone (Group I) and $32\;(57.1\%)$ treated with a combination of chemotherapy and radiation (Group II). Total radiation dose ranged from 40.5 to 83. 5 Gy (median 67.9 Gy). Radiotherapy was given with conventional technique in 9 patients $(16.4\%)$, with hyperfractionation I ($1.15\~1.2$ Gy/fr., BID) in 26 $(47.2\%)$, hyperfractionation II (1.35 Gy/fr., BID) in 18 $(32.7\%)$, and accelerated fractionation (1.6 Gy/fr., BID) in 2 $(3.6\%)$. In chemotherapy, 5-FU ($1,000\;mg/m^2$ daily for 5 consecutive days) and cisplatin ($100\;mg/m^2$ on day 1) were administered in a cycle of 3 weeks interval, and a total of 1 to 3 cycles (average 2..3 cycles) were given prior to radiation therapy. Follow up duration was $1\~195$ months (median 28 months). Results : Overall 2 and 5 year survival rates were $40.6\%\;and\;27.6\%;\;50.0\%\;and\;30.0\%$ in Group I, and $36.4\%\;and\;26.3\%$ in Group II, respectively. Complete local control rates in Group I and II were $70.0\%\;and\;67.7\%$, respectively. The response to radiotherapy and nodal stage were statistically significant prognostic factors. The complication rate was increased in Group II and was decreased in hyperfractionation. Conclusion : The response to radiotherapy and nodal stage were valid factors to indicate the degree of control over the hypopharyngeal cancer. The induction cisplatin, 5-Fu chemotherapy was not valid in terms of local control rate and survival rate, but did contribute to an increased complication rate. The use of hyperfractionation was valid to reduce the late radiation complications.

키워드

참고문헌

  1. Emami B, Spector JG. Hypopharynx. In: Perez CA, Brady LW, eds. Principles and Practice of Radiation oncology. 3rd ed. Philadelphia, PA: Lippincott Co. 1998:1045-1068
  2. Sheldon JM, Zelefsky MJ. Hypopharyngeal cancer. In: Leibel SA, Phillips TL, eds. Textbook of Radiation Oncology. 1st ed. Philadelphia, PA : Saunders Co. 1998:477-496
  3. Arrigada R, Eschwege F, Cachin Y, Richard JM. The value of combining radiotherapy with surgery in the treatment of hypopharyngeal cancer. Cancer 1983;51:1819-1825 https://doi.org/10.1002/1097-0142(19830515)51:10<1819::AID-CNCR2820511011>3.0.CO;2-G
  4. Marcial VA, Pajak TF, Kramer S, et al. Radiation therapy oncology group studies in head and cancer. Semin Oncol 1988;15:39-60
  5. Fu KK, Cooper JS, Marical VA, et al. Evolution of the radiation therapy oncology group clinical trials for head and neck cancer. Int J Radiat Oncol Biol Phys 1996;35:425-438 https://doi.org/10.1016/S0360-3016(96)80003-4
  6. Ariene AF. Cisplatine and radiation therapy in the management of locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1993;27:465-470 https://doi.org/10.1016/0360-3016(93)90260-3
  7. Pfister DG, Strong E, Harrison L, et al. Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer. J Clin Oncol 1991;9:850-859
  8. Shirinian MH, Weber RS, Lippman SM, et al. Larynx preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer. Head and Neck 1994;16:39-44 https://doi.org/10.1002/hed.2880160109
  9. Kim SJ, Wu HG, Heo DS, Park CI. Neoadjuvant chemotherapy and radiotherapy in locally advanced hypopharyngeal cancer. J Korean Soc Ther Radiol 2000;18:244-250
  10. Saman S, Kumar P, Wan J, et al. Concomitant radiation therapy and targeted cisplatin chemotherapy for the treatment of advanced pyriform sinus carcinoma : disease control and preservation of organ function. Head and Neck 1999;21:595-601 https://doi.org/10.1002/(SICI)1097-0347(199910)21:7<595::AID-HED2>3.0.CO;2-J
  11. Bensadoun RJ, Etienne MC, Dasonville O, et al. Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French ulticenter phase II study. Int J Radiat Oncol Biol Phys 1998;42:237-245
  12. Zelefsky MJ, Kraus DH, Pfister DG, et al. Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Head and Neck 1996;18:405-411 https://doi.org/10.1002/(SICI)1097-0347(199609/10)18:5<405::AID-HED3>3.0.CO;2-9
  13. Pharynx. In: Fleming ID, Cooper JS, Henson DE, eds. AJCC Cancer Staging Manual. 5th ed. Philadelphia: J.B. Lippincott. 1993:31-39
  14. Rudat V, Wannenmacher M. Role of multimodal treatment in oropharynx, larynx, and hypopharynx. Semin Surg Oncol 2001;20:66-74 https://doi.org/10.1002/ssu.1018
  15. Bachaud JM, Jonathan EC, Alzieu C, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36:999-1004 https://doi.org/10.1016/S0360-3016(96)00430-0
  16. Marcial VA, Pajak TF, Mohiuddin M, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Longterm results of the Radiation Therapy Oncology Group study 81-17. Cancer 1990;66:1861-8 https://doi.org/10.1002/1097-0142(19901101)66:9<1861::AID-CNCR2820660902>3.0.CO;2-I
  17. Kim KH, Sung MW, Rhee CS, et al. Neoadjuvant chemotherapy and radiotherapy for the treatment of advanced hypopharyngeal carcinoma. Am J Otolaryngol 1998;19:40-44 https://doi.org/10.1016/S0196-0709(98)90064-3
  18. Mercier RJ, Neal D, Mattox DE, Gates GA, Pomeroy TC, Von Hoff DD. Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 1987;60:2609-2612 https://doi.org/10.1002/1097-0142(19871201)60:11<2609::AID-CNCR2820601105>3.0.CO;2-E
  19. Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced head and neck cancer. Final report of the Southwest Oncology Group. Laryngoscope 1988;98:1205-1211
  20. Ampil FL, Campbell LC, Mills GM. Neoadjuvant chemotherapy and radiotherapy for inoperable head and neck cancer: the LSU-Shreveport experience. J La State Med Soc 1998;150:413-417
  21. Marcial VA, Pajak TF, Chang C, Yupchong L, Stetz J. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the radiation therapy oncology group (RTOG). Int J Radiat Oncol Biol Phys 1987;13:41-47 https://doi.org/10.1016/0360-3016(87)90258-6
  22. Schrader M, Schipper J, Jahnke K, Stuschke M, Sack H, Budach V. Hyperfractionated accelerated simultaneous radiochemotherapy in advanced hypopharyngeal carcinomas. Survival rate, retained function quality of life in a phase II study. HNO 1998;46:140-145 https://doi.org/10.1007/s001060050212
  23. Fu KK, Pajak TF, Trotti A, et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas : first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16 https://doi.org/10.1016/S0360-3016(00)00663-5
  24. Garden AS, Morrison WH, Clayman GL, Ang KK, Peters LJ. Early squamous cell carcinoma of the hypopharynx: outcomes of treatment with radiation alone to the primary disease. Head and Neck 1996;18:317-322 https://doi.org/10.1002/(SICI)1097-0347(199607/08)18:4<317::AID-HED2>3.0.CO;2-0
  25. Akimoto T, Mitsuhashi N, Sakurai H, et al. Reaults of radiation therapy for hypopharyngeal carcinoma : impact of accelerated hyperfractionation on prognosis. Jpn J Clin Oncol 1996;26:169-174 https://doi.org/10.1093/oxfordjournals.jjco.a023202
  26. Garden AS, Morrison WH, Ang KK, Peters LJ. Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck:a comparson of two fractionation schedules. Int J Radiat Oncol Biol Phys 1995;31:493-502 https://doi.org/10.1016/0360-3016(94)00334-H
  27. Sakata K, Aoki Y, Karasawa K, et al. Analysis of treatment results of hypopharyngeal cancer. Radiat Med 1998;16:31-36
  28. Elias MM, Hilgers FJ, Keus RB, Gregor RT, Hart AA, Balm AJ. Carcinoma of the pyriform sinus: a retrospective analysis of treatment results over a 20-year period. Clin Otolaryngol 1995;20:249-253 https://doi.org/10.1111/j.1365-2273.1995.tb01860.x
  29. Van Mierlo IJM, Levendag PC, Eijkenboom WMH, et al. Radiation therapy for cancer of the piriform sinus. Am J Clin Oncol 1995;18:502-509 https://doi.org/10.1097/00000421-199512000-00010
  30. Kramer S, Marcial VA, Pajak TF, Maclean CJ, Davis LW. Prognostic factors for loco/regional control and metastasis and the impact on survival. Int J Radiat Oncol Biol Phys 1986;12:573-578 https://doi.org/10.1016/0360-3016(86)90065-9